ELISA/assay

Rat Peroxisome Proliferators activator gamma ELISA Kit

MBS725973

48-Strip-Wells

470 USD

ELISA Kit

Rat Peroxisome Proliferators activator gamma ELISA Kit

Peroxisome Proliferators activator gamma

Rat Peroxisome Proliferators activator g ELISA Kit

Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor gamma; peroxisome proliferator-activated receptor gamma; PPAR-gamma; nuclear receptor subfamily 1 group C member 3; peroxisome proliferator-activated nuclear receptor gamma variant 1; peroxisome proliferator-activated receptor gamma; Nuclear receptor subfamily 1 group C member 3

PPAR-gamma

PPAR-g

PPARG; PPARG; GLM1; CIMT1; NR1C3; PPARG1; PPARG2; PPARgamma; NR1C3; PPAR-gamma

PPARG_HUMAN

Rat

This assay has high sensitivity and excellent specificity for detection of PPAgamma. No significant cross-reactivity or interference between PPAgamma and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between PPAgamma and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This PPAgamma ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Rat PPAgamma. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Principle of the assay: PPAgamma ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-PPAgamma antibody and an PPAgamma-HRP conjugate. The assay sample and buffer are incubated together with PPAgamma-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the PPAgamma concentration since PPAgamma from samples and PPAgamma-HRP conjugate compete for the anti-PPAgamma antibody binding site. Since the number of sites is limited, as more sites are occupied by PPAgamma from the sample, fewer sites are left to bind PPAgamma-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PPAgamma concentration in each sample is interpolated from this standard curve.

13432234

P37231.3

21,580 Da

AMPK Signaling Pathway (989139); AMPK Signaling Pathway (992181); Adipogenesis Pathway (198832); Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway (137993); Developmental Biology Pathway (477129); Energy Metabolism Pathway (198907); Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway (160977); Gene Expression Pathway (105937); Generic Transcription Pathway (105938); Huntington's Disease Pathway (83100)

This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

PPAR-gamma: a transcription factor, member of the nuclear hormone receptor superfamily. Receptor for hypolipidemic drugs and fatty acids. Preferentially expressed in adipocytes as well as in vascular smooth muscle cells and macrophage. Regulator of adipogenesis and lipid metabolism, modulates insulin sensitivity, cell proliferation and inflammation. Phosphorylated and inhibited by MAP kinase. Heterodimerizes with the retinoid X receptor. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Two splice-variant isoforms have been described. Protein type: DNA-binding; Nuclear receptor. Chromosomal Location of Human Ortholog: 3p25. Cellular Component: nucleoplasm; perinuclear region of cytoplasm; cytosol; nucleus. Molecular Function: ligand-dependent nuclear receptor activity; transcription activator binding; zinc ion binding; drug binding; alpha-actinin binding; protein phosphatase binding; retinoid X receptor binding; arachidonic acid binding; protein binding; enzyme binding; ligand-dependent nuclear receptor transcription coactivator activity; DNA binding; prostaglandin receptor activity; sequence-specific DNA binding; estrogen receptor binding; steroid hormone receptor activity; chromatin binding; transcription factor activity. Biological Process: positive regulation of transcription, DNA-dependent; heart development; negative regulation of collagen biosynthetic process; cell maturation; rhythmic process; lipid homeostasis; response to lipid; glucose homeostasis; response to caffeine; response to vitamin A; positive regulation of oligodendrocyte differentiation; placenta development; long-chain fatty acid transport; organ regeneration; cell fate commitment; monocyte differentiation; negative regulation of acute inflammatory response; regulation of circadian rhythm; response to starvation; negative regulation of telomerase activity; cellular response to insulin stimulus; response to mechanical stimulus; response to estrogen stimulus; lipoprotein transport; brown fat cell differentiation; positive regulation of fat cell differentiation; steroid hormone mediated signaling; positive regulation of transcription from RNA polymerase II promoter; fatty acid oxidation; positive regulation of transcription factor activity; negative regulation of transcription, DNA-dependent; positive regulation of phagocytosis, engulfment; negative regulation of smooth muscle cell proliferation; low-density lipoprotein receptor biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; signal transduction; epithelial cell differentiation; regulation of blood pressure; response to nutrient; caspase activation; transcription initiation from RNA polymerase II promoter; response to retinoic acid; G-protein coupled receptor protein signaling pathway; response to low density lipoprotein stimulus; white fat cell differentiation; positive regulation of fatty acid oxidation; innate immune response; gene expression; response to cold; negative regulation of cell growth; lipid metabolic process. Disease: Obesity; Carotid Intimal Medial Thickness 1; Lipodystrophy, Familial Partial, Type 3; Diabetes Mellitus, Noninsulin-dependent

48-Strip-Wells

470 USD

96-Strip-Wells

675